About The Study: This qualitative analysis characterizes the Food and Drug Administration’s (FDA’s) decision-making with respect to the regulation of mifepristone, with a particular interest in the agency’s rationale for establishing, maintaining, or modifying key components of its regulatory approach over time.
Corresponding Author: To contact the corresponding author, G. Caleb Alexander, MD, MS, email galexan9@jhmi.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.23091)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.23091?guestAccessKey=ffa9b37f-eb54-4b7f-a180-8554c58f4280&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=011226
JAMA